PDI inks one-year sales agreement

Share this article:
Contract sales firm PDI has inked a one-year sales agreement for a cardiology drug with an unnamed “top-10 pharmaceutical company.”

The initiative, expected to bring in $13 million in revenue, will target primary care physicians and cardiologists and was scheduled to begin April 2.

The announcement is viewed as a much-needed boost for PDI, which announced a decision by a “large pharma company” client not to renew a $35 million contract sales engagement with the firm. PDI previously expected that one-year deal to be extended through the end of 2007.

PDI has endured four major contract losses during the past year.

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?